Veritas Aortic Solutions, a medical device company spun out of inQB8 Medical Technologies, announced the closing of a $12 million seed financing round to support the development of its Veritas Transcatheter Valved Aortic Root Conduit (TVARC), a non-surgical treatment designed for patients with aortic root and ascending aortic diseases.
The financing round was led by a group of experienced MedTech angel investors and included significant participation from Cedars-Sinai Intellectual Property Company (CSIPCo) and existing inQB8 investors. The capital will be used to advance the TVARC platform toward first-in-human clinical use.
Veritas is developing the TVARC system to address high-risk aortic conditions, including dissections, aneurysms, and other pathologies involving the aortic root, coronary ostia, and ascending aorta. The company aims to provide a minimally invasive alternative to open-heart surgery, which remains the standard treatment option for these conditions.
As part of the financing, Chad Martinson, former Medtronic CoreValve executive and former CEO of ACOVA Integrated Health; Judd Nordquist, CEO of Ibis Scientific; and Nirdesh Gupta, Ph.D., Managing Partner of Cedars-Sinai Intellectual Property Company, joined the Veritas board of directors. They will serve alongside company co-founders Arshad Quadri, M.D., and J. Brent Ratz.
The TVARC system consists of a single permanent implant that combines a bioprosthetic aortic valve, an ascending aortic graft, and the company’s proprietary Chameleon Eye coronary perfusion ports. The device is designed to isolate diseased portions of the aorta while restoring blood flow to the coronary arteries and the rest of the body. The system is delivered through a custom transfemoral catheter intended to eliminate the need for open-heart surgery and enable controlled deployment.
Founded within inQB8 Medical Technologies and spun out as an independent company in late 2025, Veritas Aortic Solutions is focused on developing therapies for diseases affecting the aortic root, coronary arteries, and ascending aorta. The company has already advanced the TVARC program through prototyping, bench testing, and chronic animal studies.
KEY QUOTES:
“With combined mortality and morbidity rates as high as 65%, it is hard to overstate the risk associated with current surgical treatments for acute conditions of the ascending aorta. As a cardiac surgeon myself, I have performed these procedures numerous times. They are complex, challenging, and highly invasive. Endovascular options for the descending aorta and the arch have been available for a long time, but open-heart surgery remains the only approved option for patients with root and ascending aortic pathologies. It has always been a dream of mine to be able to offer these patients a faster, safer, less-invasive option, and today we are one step closer to making that a reality.”
Arshad Quadri, M.D., Co-Founder, Executive Chairman And Chief Medical Officer, Veritas Aortic Solutions
“The Veritas TVARC system represents the type of patient-centered innovation we seek to support at Cedars-Sinai. We are pleased to participate in this financing to help advance a novel endovascular approach to Aortic Root and Ascending Aortic Disease—an area where treatment options have remained largely unchanged for years despite significant patient risk. We believe this technology has the potential to meaningfully improve outcomes for patients facing life-threatening cardiovascular disease.”
Nirdesh Gupta, Ph.D., Managing Partner, Cedars-Sinai Intellectual Property Company
“After establishing the Veritas program within inQB8 Medical Technologies and rapidly advancing it through prototyping, bench testing, and successful chronic animal studies, we are honored to have the support of seasoned MedTech investors, leading physicians, and a world-class healthcare organization like Cedars-Sinai to accelerate our development and bring this technology towards its first clinical application. In our 20+ year partnership, Dr. Quadri and I have collaborated to create solutions for several cardiovascular issues. Given the complexity of Root and Ascending Aortic Diseases and the dire need for an interventional solution, I believe Veritas is poised to be the most meaningful of all in terms of patient impact.”
J. Brent Ratz, Co-Founder And Chief Executive Officer, Veritas Aortic Solutions
